Procter & Gamble Q2 EPS Beats by 1%, Guides FY2026 EPS at $6.83–7.09
Procter & Gamble reported Q2 adjusted EPS of $1.88, beating Wall Street by $0.02 on revenues of $22.21 billion, up 1.5% year-over-year, while setting FY2026 EPS guidance at $6.83–7.09. JPMorgan, UBS and Wells Fargo each lifted price targets to $165–$170, raising the consensus target to $166.70.
1. Market Prices Reflect Worst-Case Scenario
Procter & Gamble shares are trading at multi-year lows after the market largely priced in only tepid organic sales growth across its Beauty, Grooming and Fabric & Home Care segments. Consensus forecasts call for low-single-digit revenue gains over the next two years, yet a muted growth environment still supports the company’s strong free cash flow generation. With operating cash flow exceeding $16 billion over the past four quarters and a track record of mid-teens EBITDA margins, P&G’s current valuation implies a much darker outlook than its cash flow profile would suggest.
2. GDS Wealth Management Boosts Position
In the most recent 13F filing, GDS Wealth Management increased its stake in Procter & Gamble by 20.9% during the third quarter, acquiring an additional 14,060 shares and bringing its total position to 81,190 shares valued at approximately $12.48 million at quarter end. This move marked one of several sizable purchases by institutional investors in the period: PFG Investments added 870 shares, Symphony Financial added 257 shares and Inlet Private Wealth increased its holding by 172 shares. Collectively, hedge funds and institutional investors now control roughly 65.8% of the company’s float.
3. Dividend Payout Remains Robust
P&G’s latest quarterly dividend of $1.0568 per share maintains the company’s streak of annual dividend increases dating back to 1952. On an annualized basis, the dividend equates to $4.23 per share and yields approximately 2.8% on current share count. With a payout ratio near 63% against trailing EPS of $6.72 and net debt representing just 0.5 times EBITDA, the dividend appears well covered even if organic growth remains subdued.
4. Analyst Ratings Tilt Positive
Over the past quarter, major research firms have turned more constructive on Procter & Gamble. JPMorgan Chase upgraded its rating from Neutral to Overweight while raising its 12-month target by 5% and UBS raised its Buy target by 6%. Fourteen analysts currently rate the stock a Buy versus eight Hold recommendations, giving P&G a consensus Moderate Buy rating. The average price target implied by these estimates sits roughly 11% above current levels, underscoring expectations for valuation recovery as per-share earnings approach the upper end of the guided $6.83–$7.09 range for fiscal 2026.